WMT Settles Opioid Allegations for $50M, Traded Fairly Valued by GuruFocus

Walmart Inc (WMT) finalized a $50 million settlement with U.S. authorities over allegations of improperly processing invalid opioid prescriptions at its pharmacies, violating the Controlled Substances Act.

The company agreed to implement stricter compliance protocols, including a hotline for reporting suspicious activities and improved prescription monitoring systems, aiming to prevent future regulatory breaches.

According to GuruFocus' proprietary GF Value™ metric, Walmart is trading at $103.09, which is marginally 0.1% above its intrinsic value estimate of $102.94.

This near parity suggests the stock is fairly valued, offering little margin of safety but also limited downside risk based on current fundamentals.